ArticleVascular health and risk management2025
H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CVD remains the leading global cause of mortality, especially in individuals with T2D and Pre-DM, where insulin resistance increases cardiometabolic risk and early myocardial injury often goes unrecognized. This study aimed to evaluate baseline serum concentrations of H-FABP and Hs-cTnI, biomarkers linked to myocardial injury, in newly diagnosed T2D, Pre-DM, and normoglycemic individuals, to assess their predictive value for CVEs and the association between H-FABP and HOMA-IR. Methods: In a prospective cohort study of 72 medication-free participants (25 T2D, 22 Pre-DM, 25 normoglycemic) without clinical myocardial symptoms, baseline anthropometric and biochemical measurements were obtained, including H-FABP, Hs-cTnI, HbA1c, fasting glucose, fasting insulin, and HOMA-IR was calculated. Participants were followed one year to evaluate the occurrence of CVE. Results: Strong correlations between baseline H-FABP and Hs-cTnI across all glycemic groups (all p<0.01) with no significant intergroup differences. In abnormal weight T2D participants, baseline fasting insulin correlated moderately with baseline H-FABP (ρ=0.50, p=0.029) and strongly with baseline HOMA-IR (ρ=0.74, p<0.001). CVEs occurred in 33.3% of participants and were associated with elevated baseline H-FABP and Hs-cTnI (p<0.001 and p=0.001), alongside strong biomarker inter-correlation (ρ=0.64 overall; ρ=0.84 in CVEs). Both biomarkers independently predicted CVEs; H-FABP had higher sensitivity and NPV, while Hs-cTnI showed greater specificity and PPV. Glycemic status was not statistically associated with CVE occurrence, although higher HOMA-IR and insulin were observed in the CVE group (p=0.073 and p=0.054). Conclusion: These findings support H-FABP as a cardiac biomarker for myocardial injury across normoglycemic, Pre-DM, and T2D groups. The link between H-FABP and insulin resistance in individuals with greater burden of metabolic disturbance highlights its role as a cardiometabolic indicator. Both biomarkers predicted CVEs in asymptomatic individuals, with H-FABP potentially useful for early risk exclusion and Hs-cTnI for confirming high-risk status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.